Microbiome-Targeted Interventions (MBTIs)

Karen Pendergrass

Overview

A Microbiome-Targeted Intervention refers to a deliberate and purposeful manipulation of the gut microbiota’s composition and function to restore health and prevent disease.^[1] MBTIs encompass a diverse range of therapeutic approaches that vary in application, goal, and mechanisms of action. These interventions can be broadly categorized into two approaches: those that modify the entire microbial community, such as dietary modulations or fecal microbiota transplantation (FMT), and those targeting specific taxa or strains, including phage therapy, probiotics, and prebiotics.^[2] The fundamental principle underlying MBTI is that by restoring a healthy microbiota composition and optimizing microbial function through various mechanisms of action, we can modulate host responses to disease-relevant exposures and stimuli, ultimately leading to improved health outcomes.^[3] Thus, MBTIs are a key component of precision microbiome medicine, revolutionizing treatments with unparalleled precision and impact.

Microbiome-Targeted Interventions: Scope

The scope of conditions benefiting from MBTI has expanded dramatically as research has accumulated evidence for microbiome-driven pathogenesis across nearly every major organ system. Metabolic and Gastrointestinal Conditions represent the most robustly validated therapeutic area. Obesity and metabolic syndrome have shown particular responsiveness to MBTI through multiple mechanisms: targeting the microbiome by diet modulation can increase short-chain fatty acid (SCFA)-producing bacteria and reduce pathogenic taxa, leading to improved glucose metabolism and lipid profiles.^[4] Nonalcoholic fatty liver disease (NAFLD) shows significant improvement with probiotics and synbiotics, with interventions reducing liver inflammation markers and hepatic steatosis as measured by ultrasound and elastography.^[5] Irritable bowel disease, encompassing both Crohn’s disease and ulcerative colitis, represents perhaps the most clinically advanced application of MBTI. Probiotics, prebiotics, synbiotics, and particularly FMT have demonstrated efficacy in inducing remission in IBD patients, with one clinical study reporting 95% of ulcerative colitis patients achieved clinical remission eight weeks after FMT. ^[6]^[7] Type 1 and type 2 diabetes also benefit from microbiome-targeted approaches, as specific microbial taxa influence glucose homeostasis through SCFA production and immune regulation.^[8]

New Directions in MBTIs: Beyond Traditional Approaches

The future of Microbiome-Targeted Interventions (MBTIs) is rapidly evolving, moving beyond traditional probiotics and prebiotics to encompass highly sophisticated, condition-specific, and personalized strategies. This evolution is driven by advances in understanding the intricate mechanisms of host-microbe interactions, including novel approaches such as phage therapy, targeting functional shielding, developing new antimicrobials, leveraging photobiomodulation, exploring drug repurposing, supporting nutritional immunity, and new advancements and insights from the field of microbial metallomics.

Intervention	MBTI Status
Phage Therapy	Phage therapy is gaining significant traction as a precise tool for microbiome modulation. Unlike broad-spectrum antibiotics that decimate commensal bacteria along with pathogens, bacteriophages (viruses that infect bacteria) offer highly specific targeting of undesirable bacterial species without disrupting the beneficial microbiota.^[9] This precision is particularly valuable in managing infectious diseases and combating antibiotic resistance, where traditional methods fall short.^[10] Engineered phages could be designed to eliminate specific pathogens or even deliver therapeutic payloads, offering a novel strategy for infectious disease prevention and treatment. This contrasts with traditional microbiome modulation methods like probiotics and fecal microbiota transplantation (FMT), providing unparalleled specificity and adaptability in microbial targeting.^[11]
Targeting Functional Shielding and Co-aggregation	A critical area for future MBTIs involves addressing microbial “functional shielding” and co-aggregation, where certain microorganisms create protective environments that enable pathogens to thrive or resist treatments. This phenomenon is observed in cases like Candida in its hyphae stage, providing a niche for Staphylococcus aureus, or co-aggregation between Candida and Porphyromonas gingivalis. ^[12]^[13] Understanding these intricate inter-kingdom interactions is key. MBTIs will increasingly focus on disrupting these protective mechanisms. For instance, if Candida facilitates the persistence of other pathogens, interventions could aim to inhibit Candida hyphal formation or its co-aggregation properties. Developing strategies to interfere with these synergistic pathogenic alliances could dramatically improve outcomes in polymicrobial infections and chronic inflammatory conditions.
Novel Antimicrobials and Bacteriostatics	The development of novel classes of antimicrobials and bacteriostatics, such as dimethylglyoxime or gallium, represents another promising avenue. ^[14]^[15] These agents could offer more selective action against pathogens compared to conventional antibiotics, minimizing off-target effects on the beneficial microbiome. The goal is to inhibit or kill harmful microbes without broadly disrupting the delicate microbial ecosystem, thereby avoiding unintended consequences like secondary infections or the emergence of further resistance. Such targeted antimicrobials are crucial in the fight against multidrug-resistant infections.
Photobiomodulation	Photobiomodulation (PBM) is an emerging non-invasive technique that uses light to stimulate cellular function, reduce inflammation, and promote healing. Its application in microbiome medicine is exploratory but holds potential, particularly in modulating microbial communities on accessible surfaces like the skin or oral cavity. PBM could influence microbial growth, biofilm formation, or even host immune responses in a way that shifts the microbial balance towards a healthier state, potentially offering a gentle yet effective method to enhance MBTIs.
Supporting Nutritional Immunity Factors	Nutritional immunity represents one of the most ancient and fundamental defense mechanisms by which the host actively restricts the bioavailability of essential nutrients to limit pathogenic microbial growth and virulence.^[16] This mechanism extends beyond simple nutrient deprivation to a sophisticated form of chemical warfare where the host manipulates metal availability to simultaneously suppress pathogenic virulence while preserving or enhancing the fitness of commensal microbiota.^[17] The distinction between traditional micronutrient supplementation and nutritional immunity- and microbial metallomics-informed MBTIs is critical. Conventional clinical practice often assumes that nutritional deficiencies universally require supplementation (i.e. that iron-deficient patients should supplement ferrous sulfate, that zinc-deficient individuals should supplement zinc oxide or zinc citrate, that copper-depleted hosts benefit from copper gluconate.) However, in the context of dysbiosis and microbial pathogenesis, such blanket supplementation can inadvertently fuel pathogenic growth while simultaneously undermining the host’s natural antimicrobial strategies.^[18] Nutritional immunity- and microbial metallomics-informed MBTIs, by contrast, recognize that in many disease states, apparent micronutrient “deficiency” is actually an adaptive host response, a deliberate sequestration strategy designed to starve invading pathogens.^[19] Supporting nutritional immunity thus involves a fundamentally different therapeutic paradigm: rather than correcting “deficiency,” the goal becomes enhancing the host’s ability to maintain nutrient restriction while simultaneously ensuring that this restriction selectively disadvantages pathogens without compromising commensal bacteria or essential host physiology.^[20]
Advancements in Microbial Metallomics	The field of microbial metallomics, studying the role of metals in microbial life, is crucial for advancing MBTIs. Environmental heavy metals, even at trace levels, can act as cofactors for pathogens and their virlence factors, or cause mismetallation. Future MBTIs will increasingly consider these elemental interactions to develop targeted interventions. ^[21] Advancements in the field will inevitably lead to therapies that precisely target the metal-dependent pathways of pathogens or enhance host mechanisms to sequester potentially harmful metals, thereby influencing microbial virulence and host susceptibility. These interventions extend beyond simple nutrient supplementation to a sophisticated understanding of metal bioavailability and utilization within the microbial ecosystem.
Drug Repurposing	Drug repurposing represents an emerging and highly promising frontier for MBTI advancement. Rather than developing novel compounds from scratch, drug repurposing leverages the extensive safety, pharmacokinetic, and clinical data already available for FDA-approved or clinically validated drugs, dramatically accelerating the timeline from bench discovery to clinical application. ^[22] This approach is particularly valuable for MBTI development because it enables rapid translation of microbiome research findings into clinically accessible interventions while bypassing the lengthy and expensive drug development process. Many approved pharmaceuticals were originally developed for entirely different indications but possess incidental antimicrobial properties that, when applied strategically to dysbiosis, can shift microbial communities favorably. For instance, certain cardiac medications, antihistamines, and psychiatric drugs demonstrate selective antimicrobial effects against dysbiosis-driving pathogens while sparing beneficial commensals.^[23] Metformin, the first-line diabetes medication used by hundreds of millions of patients, exemplifies this principle: originally developed as an antidiabetic agent, metformin’s effects on glucose metabolism are now understood to work partly through direct modulation of gut dysbiosis, selectively promoting growth of SCFA-producing commensals like Akkermansia muciniphila and Faecalibacterium prausnitzii.^[24] Recognition of this mechanism has led to emerging clinical interest in metformin as an MBTI for obesity and metabolic syndrome independent of its glucose-lowering effects.
Advances in Targeted Prebiotics	Prebiotics represent one of the oldest and most naturalistic MBTI approaches. However, traditional prebiotic development has been relatively crude, with most prebiotics being broadly fermented by multiple bacterial taxa without specific selectivity for target species.^[25] One of the most profound discoveries emerging from precision prebiotic research involves the relationship between prebiotic molecular weight and microbial selectivity , ensuring prebiotic compabitility with the desired outcomes. ^[26] This principle fundamentally challenges the traditional “one-size-fits-all” prebiotic approach, which is crucial to the advancement of the proper use of fibers in microbiome medicine applications.

Frequently Asked Questions

What is Microbiome-Targeted Interventions (MBTIs)?

Quick answer: A Microbiome-Targeted Intervention refers to a deliberate and purposeful manipulation of the gut microbiota’s composition and function to restore health and prevent disease.^[1] MBTIs encompass a diverse range of therapeutic approaches that vary in application, goal, and mechanisms of action. These interventions can be broadly categorized into two approaches: those that modify the entire microbial community, such as dietary modulations or , and those targeting specific taxa or strains, including , probiotics, and prebiotics.^[2] The fundamental principle underlying MBTI is that by restoring a healthy microbiota composition and optimizing microbial function through various mechanisms of action, we can modulate host responses to disease-relevant exposures and stimuli, ultimately leading to improved health outcomes.^[3] Thus, MBTIs are a key component of precision microbiome medicine, revolutionizing treatments with unparalleled precision and impact.

What helps treat Microbiome-Targeted Interventions (MBTIs)?

Quick answer: The scope of conditions benefiting from MBTI has expanded dramatically as research has accumulated evidence for microbiome-driven pathogenesis across nearly every major organ system. Metabolic and Gastrointestinal Conditions represent the most robustly validated therapeutic area. Obesity and metabolic syndrome have shown particular responsiveness to MBTI through multiple mechanisms: targeting the microbiome by diet modulation can increase -producing bacteria and reduce pathogenic taxa, leading to improved glucose metabolism and lipid profiles.^[4] Nonalcoholic fatty liver disease (NAFLD) shows significant improvement with probiotics and synbiotics, with interventions reducing liver inflammation markers and hepatic steatosis as measured by ultrasound and elastography.^[5] Irritable bowel disease, encompassing both and ulcerative colitis, represents perhaps the most clinically advanced application of MBTI. Probiotics, prebiotics, synbiotics, and particularly FMT have demonstrated efficacy in inducing remission in IBD patients, with one clinical study reporting 95% of ulcerative colitis patients achieved clinical remission eight weeks after FMT. ^[6]^[7] Type 1 and type 2 diabetes also benefit from microbiome-targeted approaches, as specific microbial taxa influence glucose homeostasis through SCFA production and immune regulation.^[8]

Research Feed

November 19, 2021

Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.